These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 14707138)
1. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. Whitehurst AW; Robinson FL; Moore MS; Cobb MH J Biol Chem; 2004 Mar; 279(13):12840-7. PubMed ID: 14707138 [TBL] [Abstract][Full Text] [Related]
2. ERK2 enters the nucleus by a carrier-independent mechanism. Whitehurst AW; Wilsbacher JL; You Y; Luby-Phelps K; Moore MS; Cobb MH Proc Natl Acad Sci U S A; 2002 May; 99(11):7496-501. PubMed ID: 12032311 [TBL] [Abstract][Full Text] [Related]
3. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Eblen ST; Catling AD; Assanah MC; Weber MJ Mol Cell Biol; 2001 Jan; 21(1):249-59. PubMed ID: 11113199 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1. Robinson FL; Whitehurst AW; Raman M; Cobb MH J Biol Chem; 2002 Apr; 277(17):14844-52. PubMed ID: 11823456 [TBL] [Abstract][Full Text] [Related]
5. Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains. Callaway K; Rainey MA; Dalby KN Biochim Biophys Acta; 2005 Dec; 1754(1-2):316-23. PubMed ID: 16324895 [TBL] [Abstract][Full Text] [Related]
6. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. Chou FL; Hill JM; Hsieh JC; Pouyssegur J; Brunet A; Glading A; Uberall F; Ramos JW; Werner MH; Ginsberg MH J Biol Chem; 2003 Dec; 278(52):52587-97. PubMed ID: 14506247 [TBL] [Abstract][Full Text] [Related]
7. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Formstecher E; Ramos JW; Fauquet M; Calderwood DA; Hsieh JC; Canton B; Nguyen XT; Barnier JV; Camonis J; Ginsberg MH; Chneiweiss H Dev Cell; 2001 Aug; 1(2):239-50. PubMed ID: 11702783 [TBL] [Abstract][Full Text] [Related]
8. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. Callaway K; Abramczyk O; Martin L; Dalby KN Biochemistry; 2007 Aug; 46(32):9187-98. PubMed ID: 17658892 [TBL] [Abstract][Full Text] [Related]
9. Nuclear shuttling of mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinase (ERK) 2) was dynamically controlled by MAP/ERK kinase after antigen stimulation in RBL-2H3 cells. Furuno T; Hirashima N; Onizawa S; Sagiya N; Nakanishi M J Immunol; 2001 Apr; 166(7):4416-21. PubMed ID: 11254696 [TBL] [Abstract][Full Text] [Related]
10. Reconstitution of the nuclear transport of the MAP kinase ERK2. Jivan A; Ranganathan A; Cobb MH Methods Mol Biol; 2010; 661():273-85. PubMed ID: 20811989 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor and protein kinase C signaling to ERK2: spatiotemporal regulation of ERK2 by dual specificity phosphatases. Caunt CJ; Rivers CA; Conway-Campbell BL; Norman MR; McArdle CA J Biol Chem; 2008 Mar; 283(10):6241-52. PubMed ID: 18178562 [TBL] [Abstract][Full Text] [Related]
14. Profound conformational changes of PED/PEA-15 in ERK2 complex revealed by NMR backbone dynamics. Twomey EC; Cordasco DF; Wei Y Biochim Biophys Acta; 2012 Dec; 1824(12):1382-93. PubMed ID: 22820249 [TBL] [Abstract][Full Text] [Related]
15. Identification of a C-terminal region that is required for the nuclear translocation of ERK2 by passive diffusion. Shibayama S; Shibata-Seita R; Miura K; Kirino Y; Takishima K J Biol Chem; 2002 Oct; 277(40):37777-82. PubMed ID: 12149268 [TBL] [Abstract][Full Text] [Related]
16. Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal. Karlsson M; Mathers J; Dickinson RJ; Mandl M; Keyse SM J Biol Chem; 2004 Oct; 279(40):41882-91. PubMed ID: 15269220 [TBL] [Abstract][Full Text] [Related]
17. Identification of a cytoplasmic-retention sequence in ERK2. Rubinfeld H; Hanoch T; Seger R J Biol Chem; 1999 Oct; 274(43):30349-52. PubMed ID: 10521408 [TBL] [Abstract][Full Text] [Related]
18. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates. Zhang J; Zhou B; Zheng CF; Zhang ZY J Biol Chem; 2003 Aug; 278(32):29901-12. PubMed ID: 12754209 [TBL] [Abstract][Full Text] [Related]
19. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Robinson MJ; Stippec SA; Goldsmith E; White MA; Cobb MH Curr Biol; 1998 Oct; 8(21):1141-50. PubMed ID: 9799732 [TBL] [Abstract][Full Text] [Related]